- Home
- CEPS vs STRO Comparison
CEPS vs STRO Comparison
Compare CEPS & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CEPS | STRO |
|---|---|---|
| Founded | 2021 | 2003 |
| Country | United States | United States |
| Employees | N/A | 128 |
| Industry | Blank Checks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 148.2M | 159.5M |
| IPO Year | 2026 | 2018 |
Fundamental Metrics
Financial Performance| Metric | CEPS | STRO |
|---|---|---|
| Price | $10.21 | $9.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $47.23 |
| AVG Volume (30 Days) | 58.6K | ★ 323.7K |
| Earning Date | 01-01-0001 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $38,419,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.05 | $0.72 |
| 52 Week High | $10.45 | $43.85 |
Technical Indicators
Market Signals| Indicator | CEPS | STRO |
|---|---|---|
| Relative Strength Index (RSI) | 49.46 | 35.55 |
| Support Level | $10.07 | $8.11 |
| Resistance Level | $10.24 | $11.80 |
| Average True Range (ATR) | 0.04 | 0.82 |
| MACD | -0.00 | 0.25 |
| Stochastic Oscillator | 63.16 | 41.46 |
Price Performance
Historical ComparisonAbout CEPS Cantor Equity Partners VI Inc. Class A Ordinary Shares
Cantor Equity Partners VI Inc is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.